Sosei Heptares doses first patient in schizophrenia drug trial 04-Jul-2023 By Isabel Cameron Sosei Heptares has dosed the first subject in a phase 1 trial evaluating HTL’149, a first-in-class GPR52 agonist, which represents a novel mechanism of action for the treatment of schizophrenia and related neurological diseases.
Beyond schizophrenia: The promise of long-acting injectables 27-Oct-2021 By Jane Byrne Long-acting injectables have huge untapped clinical potential for patients and caregivers, say experts.